Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer

Most patients with thyroid cancer will evolve very well with current therapies. However, 10–30% of these patients will present recurrent disease and some of them will eventually die. IL-10 is an anti-inflammatory and immunosuppressive cytokine that can contribute to the immune escape of neoplastic c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2017-02, Vol.66 (2), p.141-148
Main Authors: Cunha, Lucas Leite, Morari, Elaine Cristina, Nonogaki, Sueli, Marcello, Marjory Alana, Soares, Fernando Augusto, Vassallo, José, Ward, Laura Sterian
Format: Article
Language:English
Subjects:
Adenocarcinoma, Follicular - immunology
Adenocarcinoma, Follicular - metabolism
Adenocarcinoma, Follicular - pathology
Antigens
Biobanks
Cancer Research
Cancer therapies
Cytokines
Female
Humans
Immunohistochemistry
Immunology
Interleukin-10 - biosynthesis
Interleukin-10 - immunology
Investigations
Male
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Oncology
Original
Original Article
Pathology
Prognosis
Retrospective Studies
Survival Rate
Thyroid cancer
Thyroid Neoplasms - immunology
Thyroid Neoplasms - metabolism
Thyroid Neoplasms - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most patients with thyroid cancer will evolve very well with current therapies. However, 10–30% of these patients will present recurrent disease and some of them will eventually die. IL-10 is an anti-inflammatory and immunosuppressive cytokine that can contribute to the immune escape of neoplastic cells. We aimed to investigate IL-10 as a molecular marker to improve the clinical management of patients with thyroid cancer. We retrospectively studied 162 patients with follicular cell-derived thyroid cancer who attended to our institution, including 63 classic papillary thyroid carcinomas, 46 follicular variant of papillary thyroid carcinomas, 11 poorly differentiated thyroid carcinomas and 42 follicular thyroid carcinomas. Patients were treated according to current guidelines and followed-up for 1–150 months. Additionally, we studied 96 samples of non-malignant tissues. We investigated the expression of IL-10 in tumor cells by semiquantitative and quantitative methods. Malignant tissues presented higher positivity (0.773 ± 0.140) than non-malignant samples (0.623 ± 0.190; p  
ISSN:0340-7004
1432-0851
DOI:10.1007/s00262-016-1924-4